Camurus AB (STO: CAMX), a Swedish research-based pharmaceutical company, announced on Monday the assignment by the US Food and Drug Administration (FDA) of a Prescription Drug User Fee Act (PDUFA) goal date of 26 December 2018 for its investigational weekly and monthly buprenorphine depots, CAM2038, for the treatment of adults with opioid use disorder (OUD).
Reportedly, the FDA considers the resubmission of the New Drug Application (NDA) by Camurus' US partner Braeburn a complete response to the 19 January 2018 action letter.
CAM2038 has demonstrated the potential to improve clinical outcomes compared to standard treatment and could significantly reduce the risks, burdens and stigma associated with daily medication. If approved, CAM2038 would be the first long-acting treatment for OUD available in both weekly and monthly formulations for use through all stages of a patient's treatment journey.
Formulated with Camurus' proprietary FluidCrystal injection depot technology, CAM2038 is designed to enable dose matching to existing sublingual buprenorphine formulations and for treatment initiation without the need to first stabilise patients on daily transmucosal buprenorphine products.
In November 2017, the FDA's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee had jointly voted 17-3 for recommending approval of CAM2038. The Advisory Committee's recommendation was based on a review of results from seven phase 1-3 clinical trials, five of which were in patients with opioid dependence.
According to the company, a core component of the NDA submission is the positive results from a pivotal phase 3 randomised, double-blind, double -dummy, active-controlled study of CAM2038 versus daily sublingual buprenorphine naloxone in patients with OUD, recently published in JAMA Internal Medicine.
CAM2038 is under regulatory review for marketing authorisation in the EU and Australia.
Camurus is committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients